Europe Cancer Diagnostics Market – Industry Trends and Forecast to 2026

  • Healthcare IT
  • Upcoming Report
  • Nov 2019
  • Europe
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Europe Cancer Diagnostics Market By Type (Laboratory Tests, Genetic Tests, Tumor Biomarkers Tests, Imaging, Endoscopy, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, Others), Technology (Instrument Based, Platform-Based, Tumor Biomarker Tests), Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Pancreatic Cancer, Ovarian Cancer, Others), End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others), Country (Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe) – Industry Trends and Forecast to 2026

Market Analysis: Europe Cancer Diagnostics Market

Europe cancer diagnostics market is registering a substantial CAGR in the forecast period of 2019-2026. This growth in market value can be attributed to the technological developments in various fields such as imaging, biomarkers, biopsy and endoscopy.

Market Definition: Europe Cancer Diagnostics Market

Cancer diagnosis is a method for the identification of different biomarkers, proteins and certain signs that aid in the discovery of cancerous tumors in patients. The identification of certain biomarkers or proteins that are present in cancer diseases helps in the diagnosis process. The cancer screening process involves the use of certain techniques or instruments commonly used in the diagnosis of cancer. Healthcare professionals are therefore focusing on developing innovative diagnosis and rehabilitation approaches to monitor epidemic rates. Early detection improves the effectiveness of treatment regimens.

Market Drivers

  • Initiatives undertaken by governments and global health organizations to spread awareness about cancer, drives the market growth
  • Support of FDA in the biomarker development, drives the market growth
  • Rising occurrence of cancer with increasing aging population, drives the market growth
  • New flow cytometry reagents for diagnostics and drug discovery, drives the market growth

Market Restraints

  • The high cost of diagnostic procedures for cancers on the market, is perceived to be a restraint on market growth
  • Due to presence of specific regulations and standards for the authorization and sale of clinical cancer products and services, hampering the market growth
  • Lack of skilled and experienced personnel, hindering the growth of market

Segmentation: Europe Cancer Diagnostics Market

By Type

  • Laboratory Tests
  • Genetic Tests
  • Tumor Biomarkers Tests
  • Imaging
  • Endoscopy
  • Biopsy
  • Liquid Biopsy
  • Immunohistochemistry
  • In Situ Hybridization
  • Others

By Technology

  • Instrument Based

    • Biopsies

      • Endoscopic Biopsy
      • Bone Marrow Biopsy
      • Needle Biopsy
      • Others
      • Liquid Biopsy

        • Diagnostic Imaging

          • Magnetic Resonance Imaging (MRI)
          • Computed Tomography (CT)
          • Mammography
          • Ultrasound
          • Positron Emission Tomography

            • Standalone Positron Emission Tomography
            • Hybrid Position Emission Tomography

  • Platform-Based

    • Immunohistochemistry (IHC)
    • Polymerase Chain Reaction (PCR)
    • Next Generation Sequencing (NGS)
    • Flow Cytometry
    • In-Situ Hybridization (ISH)
    • Microarrays
    • Others

  • Tumor Biomarker Tests

    • Alpha-Fetoprotein (AFP) Tests
    • BRCA Tests
    • ALK Tests
    • Carcinoembryonic Antigen (CEA) Tests
    • KRAS Mutation Tests
    • HER2 Tests
    • EGFR Mutation Tests
    • CA-19 Radioimmunoassay Tests
    • Circulating Tumor Cells (CTC) Tests
    • Prostate-Specific Antigen (PSA) Tests
    • Others

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

By End User

  • Cancer Research Institutes
  • Diagnostic Laboratories
  • Hospitals
  • Others

By Country

  • Germany
  • Italy
  • U.K.
  • France
  • Spain
  • Netherlands
  • Belgium
  • Switzerland
  • Turkey
  • Russia
  • Rest of Europe

Key Developments in the Market:

  • In April 2016, Agena Bioscience, Inc. had announced the launch of its MassARRAY Dx CE-IVD services in Europe. In addition to the MassARRAY Dx instrumentation, two specific diagnostic panels are also available, the MassARRAY Dx Colon Panel and the MassARRAY Dx Lung Panel. These research panels promote targeted diagnosis and better patient care by quick review of medically actionable mutations found in lung and colon cancer. With the launch of this product, the company will extend its business growth which helps to increase sales and revenue.
  • In June 2015, BioNTech AG has launched MammaTyper, a CE-IVD marked molecular diagnostic test which has a molecular diagnostic procedure for breast cancer patients by molecular subtyping of normal tumor tissue for standard use in pathology laboratories. With the launch of this product company will expand its business as well as its product portfolio which helps in growing revenue of the company.

Competitive Analysis:

Europe cancer diagnostics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cancer diagnostics market for Europe.

Key Market Competitors:

Few of the major market competitors currently working in the Europe cancer diagnostics market are Siemens Healthcare GmbH, BioNTech SE, Abbott, Agilent Technologies, Inc., BD, bioMérieux SA, NeoGenomics Laboratories, Inc., Telerad Tech., F. Hoffmann-La Roche Ltd, GENERAL ELECTRIC, Hologic, Inc., Illumina, Inc., QIAGEN, BioGenex, and Koninklijke Philips N.V. among others.

Research Methodology: Europe Cancer Diagnostics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others

Reasons to Purchase this Report

  • Current and future of Europe cancer diagnostics market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)


Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us